Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 143

1.

Long-term outcomes with medications for attention-deficit hyperactivity disorder: current status of knowledge.

Huang YS, Tsai MH.

CNS Drugs. 2011 Jul;25(7):539-54. doi: 10.2165/11589380-000000000-00000. Review. Erratum in: CNS Drugs. 2011 Nov 1;25(11):932. Dosage error in article text.

PMID:
21699268
2.

Cost effectiveness of guanfacine extended release as an adjunctive therapy to a stimulant compared with stimulant monotherapy for the treatment of attention-deficit hyperactivity disorder in children and adolescents.

Sikirica V, Haim Erder M, Xie J, Macaulay D, Diener M, Hodgkins P, Wu EQ.

Pharmacoeconomics. 2012 Aug 1;30(8):e1-15. doi: 10.2165/11632920-000000000-00000.

3.

Cost effectiveness of guanfacine extended-release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder: application of a matching-adjusted indirect comparison.

Erder MH, Xie J, Signorovitch JE, Chen KS, Hodgkins P, Lu M, Wu EQ, Sikirica V.

Appl Health Econ Health Policy. 2012 Nov 1;10(6):381-95. doi: 10.2165/11641870-000000000-00000. Erratum in: Appl Health Econ Health Policy. 2013 Jun;11(3):309. Dosage error in published abstract; MEDLINE/PubMed abstract corrected.

PMID:
23113551
4.

Attention-deficit hyperactivity disorder: recent advances in paediatric pharmacotherapy.

May DE, Kratochvil CJ.

Drugs. 2010;70(1):15-40. doi: 10.2165/11530540-000000000-00000.

PMID:
20030423
5.

Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit/hyperactivity disorder: a randomized, controlled, phase III trial.

Hervas A, Huss M, Johnson M, McNicholas F, van Stralen J, Sreckovic S, Lyne A, Bloomfield R, Sikirica V, Robertson B.

Eur Neuropsychopharmacol. 2014 Dec;24(12):1861-72. doi: 10.1016/j.euroneuro.2014.09.014. Epub 2014 Oct 23.

6.

Effects of FDA advisories on the pharmacologic treatment of ADHD, 2004-2008.

Kornfield R, Watson S, Higashi AS, Conti RM, Dusetzina SB, Garfield CF, Dorsey ER, Huskamp HA, Alexander GC.

Psychiatr Serv. 2013 Apr 1;64(4):339-46. doi: 10.1176/appi.ps.201200147.

7.
8.

Pharmacotherapy of attention-deficit hyperactivity disorder in adolescents.

Childress AC, Berry SA.

Drugs. 2012 Feb 12;72(3):309-25. doi: 10.2165/11599580-000000000-00000. Review.

PMID:
22316347
9.

Treatment of Attention-Deficit/Hyperactivity Disorder in Adolescents: A Systematic Review.

Chan E, Fogler JM, Hammerness PG.

JAMA. 2016 May 10;315(18):1997-2008. doi: 10.1001/jama.2016.5453. Review.

PMID:
27163988
10.

Advances in the treatment of attention-deficit/hyperactivity disorder: a guide for pediatric neurologists.

Wigal SB, Chae S, Patel A, Steinberg-Epstein R.

Semin Pediatr Neurol. 2010 Dec;17(4):230-6. doi: 10.1016/j.spen.2010.10.005. Review.

PMID:
21183129
11.

Efficacy and tolerability of pharmacotherapies for attention-deficit hyperactivity disorder in adults.

Santosh PJ, Sattar S, Canagaratnam M.

CNS Drugs. 2011 Sep 1;25(9):737-63. doi: 10.2165/11593070-000000000-00000. Review.

PMID:
21870887
12.

Guanfacine extended release as adjunctive therapy to psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder.

Childress AC.

Adv Ther. 2012 May;29(5):385-400. doi: 10.1007/s12325-012-0020-1. Epub 2012 May 18. Review.

PMID:
22610723
13.

Evidence-based pharmacotherapy for attention-deficit hyperactivity disorder.

Biederman J, Spencer T, Wilens T.

Int J Neuropsychopharmacol. 2004 Mar;7(1):77-97. Epub 2004 Jan 21. Review.

PMID:
14733627
14.

Comparative efficacy of guanfacine extended release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: applying matching-adjusted indirect comparison methodology.

Sikirica V, Findling RL, Signorovitch J, Erder MH, Dammerman R, Hodgkins P, Lu M, Xie J, Wu EQ.

CNS Drugs. 2013 Nov;27(11):943-53. doi: 10.1007/s40263-013-0102-x.

15.

Mechanism of action of agents used in attention-deficit/hyperactivity disorder.

Wilens TE.

J Clin Psychiatry. 2006;67 Suppl 8:32-8. Review.

16.
17.

Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder.

Martinez-Raga J, Knecht C, Szerman N, Martinez MI.

CNS Drugs. 2013 Jan;27(1):15-30. doi: 10.1007/s40263-012-0019-9. Review.

PMID:
23160939
18.

A systematic review of combination therapy with stimulants and atomoxetine for attention-deficit/hyperactivity disorder, including patient characteristics, treatment strategies, effectiveness, and tolerability.

Treuer T, Gau SS, Méndez L, Montgomery W, Monk JA, Altin M, Wu S, Lin CC, Dueñas HJ.

J Child Adolesc Psychopharmacol. 2013 Apr;23(3):179-93. doi: 10.1089/cap.2012.0093. Epub 2013 Apr 6. Review.

19.

Current and Investigational Medication Delivery Systems for Treating Attention-Deficit/Hyperactivity Disorder.

Jain R, Katic A.

Prim Care Companion CNS Disord. 2016 Aug 18;18(4). doi: 10.4088/PCC.16r01979. Review.

20.

Long-term efficacy and safety of treatment with stimulants and atomoxetine in adult ADHD: a review of controlled and naturalistic studies.

Fredriksen M, Halmøy A, Faraone SV, Haavik J.

Eur Neuropsychopharmacol. 2013 Jun;23(6):508-27. doi: 10.1016/j.euroneuro.2012.07.016. Epub 2012 Aug 20. Review.

PMID:
22917983

Supplemental Content

Support Center